Abstract
The inhibition of essential enzymes in microbial pathogens offers a route to treatment of infectious diseases. However, although the biology of the organism dictates a need for a particular enzyme activity, this does not necessarily mean that the enzyme is a good drug target. The chemistry of the active site (size, shape and properties) determines the likelihood of finding a molecule with the right properties to influence drug discovery. Discriminating between good and less-good targets is important. Studies on enzymes involved in the regulation of oxidative stress and pterin/folate metabolism of trypanosomatid parasites and isoprenoid precursor biosynthesis in bacteria and apicomplexan parasites illustrates a range of active sites representing those that are challenging with respect to the discovery of potent inhibitors, to others that provide more promising opportunities in drug discovery.
Original language | English |
---|---|
Pages (from-to) | 980-984 |
Number of pages | 5 |
Journal | Biochemical Society Transactions |
Volume | 35 |
DOIs | |
Publication status | Published - Nov 2007 |
Keywords
- antimicrobial drug
- enzyme inhibition
- isoprenoid
- non-mevalonate pathway
- pteridine reductase
- trypanothione reductase
- ISOPRENOID PRECURSOR BIOSYNTHESIS
- MAJOR PTERIDINE REDUCTASE
- NON-MEVALONATE PATHWAY
- TRYPANOTHIONE REDUCTASE
- CRYSTAL-STRUCTURE
- LEISHMANIA-MAJOR
- 2,4-CYCLODIPHOSPHATE SYNTHASE
- CRITHIDIA-FASCICULATA
- MAXIMAL AFFINITY
- ESSENTIAL ENZYME